Research
Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto
Rico
Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto
Rico
Vancouver, B.C. - November 21, 2017
(Investorideas.com Newswire) Veritas Pharma Inc.- Cannabis and Biopharma News
alert - (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the
"Company") reports that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.
(Investorideas.com Newswire) Veritas Pharma Inc.- Cannabis and Biopharma News
alert - (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the
"Company") reports that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.